The Science of Addiction in 2026: What We Actually Know
Addiction is a brain disease, genetics matter, and the science is moving faster than most clinicians can keep up with.
Body: [Draft covers: brain-disease model (mesolimbic dopamine, prefrontal control), genetic contribution (~50%), adolescent vulnerability, stress-relapse cycle, evidence for MAT, psychedelics renaissance (MDMA, psilocybin, ibogaine research), neuromodulation (TMS), digital therapeutics, and the NIH HEAL Initiative’s ~$500M/year investment. Clear disclaimer: brain-disease model doesn’t erase personal agency — it explains why willpower alone is insufficient.]
Related: Psychedelics research in 2026 | TMS for addiction — what the evidence says | “Addiction is a brain disease” — what that actually means.
Sources Cited
- 01.A
- 02.Ahttps://heal.nih.govNIH HEAL Initiative
Filed Under
Peer-Reviewed ResearchMAT — BuprenorphineFederal
Continue reading
More from this section
RFK Jr. Put Psychedelics on a Federal Fast Lane. Here's Who Stands to Benefit.
A Trump executive order on April 18 fast-tracks psychedelic therapies through FDA review, and the FDA awarded National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics. Compass is targeting a rolling NDA submission in Q4 2026.
Science & MedicineThree Days Away: The FDA Is About to Rule on the First New Quit-Smoking Drug in 20 Years
The FDA's PDUFA deadline for cytisinicline is June 20, 2026 — three days away. If approved, it would be the first new FDA-approved smoking cessation drug since varenicline in 2006, and the foundation for a coming vaping cessation program.
Science & MedicineThe Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.